Project Grant R01EY038941
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $100K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- The National Institute for Minority Health and Health Disparities awarded Massachusetts Eye and Ear Infirmary $1,009,557 on August 1, 2026, under the Minority Health and Health Disparities Research program (CFDA 93.307) to conduct a multi-level technology-enabled intervention study comparing hybrid telemedical visits and in-person visits for managing diabetic retinopathy. The recipient will conduct a single-institution, block-stratified randomized prospective clinical trial enrolling 472...
- The National Eye Institute, part of the National Institutes of Health, awarded the University of New Mexico Health Sciences Center $350,000 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate neutrophil extracellular traps and chemokine signaling in blood-retinal barrier disruption in diabetic retinopathy. The funded research targets mechanisms underlying diabetic retinopathy, the leading cause of vision loss in middle-aged adults....
- The National Eye Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $439,174 to the Regents of the University of Minnesota on September 1, 2026, under the Vision Research program (CFDA 93.867) to conduct the first study quantifying how autonomous artificial intelligence diagnostic systems expand access to diabetic retinopathy screening and treatment. The project will use 100% of Medicare claims data to identify adoption of FDA-approved...
- The National Eye Institute awarded The Schepens Eye Research Institute $858,394 on August 1, 2026, under the Vision Research program (CFDA 93.867) to develop multimodal foundation models for eye disease screening and prognosis. The research develops a vision-language foundation model trained on pairs of retinal images and clinical notes to enable downstream supervised models for detection and progression prediction of age-related macular degeneration, diabetic retinopathy, and glaucoma. The...
- The National Eye Institute awarded the University of Rochester $684,914 on July 1, 2026, under the Vision Research program (CFDA 93.867) to develop human induced pluripotent stem cell (hiPSC)-derived retinal tissue models for disease research and cell-based therapeutic applications. The award funds two complementary aims. Aim 1 develops a microphysiological model of comprehensive hiPSC-derived retina that emulates the physiological spherical geometry of the human retina in vivo, suitable for...
- The National Institutes of Health National Eye Institute awarded the University of North Carolina at Charlotte $617,244 on May 1, 2026, under the Vision Research program (CFDA 93.867) to develop distributed federated learning approaches for multi-task machine learning models applied to diabetic retinopathy diagnosis, prognosis, and treatment assessment. The project establishes federated learning frameworks that train machine learning models across multiple institutions without centralizing...
- The National Eye Institute awarded the University of Alabama at Birmingham $668,581 on April 1, 2026, under the Vision Research program (CFDA 93.867) to investigate bacterial-derived metabolites in diabetic retinopathy. Work is performed in Birmingham, Alabama, with a completion date of March 31, 2030. The recipient will conduct research on how gut microbiota-derived metabolites, particularly tryptophan metabolites, influence the development and progression of diabetic retinopathy. Prior work...
- The National Eye Institute awarded Pennsylvania State University's Penn State Milton S. Hershey Medical Center $430,650 on June 1, 2026, under the Vision Research program (CFDA 93.867) to conduct exploratory and developmental research on the renal-retinal axis in diabetic retinopathy. The research addresses an unmet clinical need for preventative therapeutic strategies targeting the underlying molecular events that cause diabetic retinopathy in its early stages. Current standard-of-care...
- The National Eye Institute, part of the Department of Health and Human Services, awarded Fasda Inc. $292,058 on September 1, 2026, under the Vision Research program (CFDA 93.867) to develop and validate Retinal Full-Field Amplitude Speckle Decorrelation Angiography (R-FASDA), an innovative imaging device for detecting neovascularization in diabetic retinopathy patients. R-FASDA addresses a gap in current screening capabilities by delivering high-resolution, noninvasive visualization of retinal...
- The National Eye Institute awarded the University of Utah $759,312 on July 1, 2026, under the Vision Research program (CFDA 93.867) to conduct the Community Eye Connect (CEC) Trial, a multi-level health informatics intervention designed to increase follow-up rates for patients with positive diabetic retinopathy screening identified through telemedicine. The trial tests a theoretically-driven, two-level intervention targeting clinic processes and patient engagement to address a documented gap...